Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson Sells 142,180 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 142,180 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Gilead Sciences Stock Up 1.2 %

Shares of GILD traded up $1.18 during mid-day trading on Monday, hitting $98.38. 10,509,697 shares of the company’s stock were exchanged, compared to its average volume of 7,014,780. The firm has a fifty day moving average of $92.42 and a two-hundred day moving average of $85.96. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $99.45. The stock has a market cap of $122.61 billion, a price-to-earnings ratio of 1,093.11, a P/E/G ratio of 1.37 and a beta of 0.18. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the prior year, the business posted $2.29 EPS. Gilead Sciences’s quarterly revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GILD. Avior Wealth Management LLC grew its stake in Gilead Sciences by 1.2% in the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 108 shares during the last quarter. Southland Equity Partners LLC grew its stake in Gilead Sciences by 3.6% in the 4th quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 110 shares during the last quarter. Concord Asset Management LLC VA grew its stake in Gilead Sciences by 3.8% in the 3rd quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 111 shares during the last quarter. Berkshire Bank grew its stake in Gilead Sciences by 3.4% in the 4th quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company’s stock valued at $314,000 after buying an additional 111 shares during the last quarter. Finally, TFB Advisors LLC grew its stake in Gilead Sciences by 1.2% in the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $788,000 after buying an additional 116 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Morgan Stanley upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $87.00 to $113.00 in a report on Friday, January 10th. Truist Financial raised their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Finally, Bank of America restated a “buy” rating and set a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.